Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | ALOX15B | O15296 | 1/20 | 0.47 |
| ▸ | PIM1 | P11309 | 2/20 | 0.45 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.45 |
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.43 |
| ▸ | TLR8 | Q9NR97 | 11/20 | 0.42 |
| ▸ | TLR7 | Q9NYK1 | 11/20 | 0.42 |
| ▸ | TLR9 | Q9NR96 | 10/20 | 0.42 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5375172 | 0.78 | MAP2K4 (0.45) | PIM1PIM2CSNK1DTLR8TLR7 | |
| SCHEMBL5381615 | 0.78 | MKNK1 (0.55) | ALDH1A1PIM1CSNK1DMAP2K4 | |
| SCHEMBL21338444 | 0.75 | — | — | |
| SCHEMBL15239508 | 0.75 | — | — | |
| SCHEMBL4045622 | 0.74 | CSNK1D (0.58) | CSNK1DTLR8TLR7TLR9MAP2K4 | |
| SCHEMBL17801040 | 0.73 | TLR9 (0.51) | TLR8TLR7TLR9 | |
| SCHEMBL5389332 | 0.72 | CSNK1D (0.58) | PIM1PIM2CSNK1DTLR8TLR7 | |
| SCHEMBL5390983 | 0.71 | CSNK1D (0.52) | ALDH1A1CSNK1DTLR8TLR7TLR9 | |
| SCHEMBL2247489 | 0.71 | NPC1 (0.53) | CYP2C19ALDH1A1ALOX15BCA1CA2 | |
| SCHEMBL15248264 | 0.71 | TLR9 (0.46) | CYP2C19ALDH1A1ALOX15BTLR8TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7211594-B2 | Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2007-05-01 | — | — | US | claimed |
| EP-1618093-A2 | INDAZOLE DERIVATIVES AS JNK INHIBITORS | Signal Pharmaceuticals LLC (US) | 2006-01-25 | — | — | EP | claimed |
| WO-2004094388-A2 | INDAZOLE DERIVATIVES AS JNK INHIBITORS | SIGNAL PHARMACEUTICALS, LLC (US) | 2004-11-04 | — | — | WO | claimed |
| US-20040127536-A1 | Methods for treating an inflammatory condition or inhibiting JNK | SIGNAL PHARMACEUTICALS, LLC | 2004-07-01 | — | — | US | claimed |
| US-7211594-B2 | Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2007-05-01 | — | — | US | disclosed |
| US-7211594-B2 | Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2007-05-01 | — | — | US | disclosed |
| US-20070060616-A1 | Methods for treating, preventing and managing chronic lymphocytic leukemia with indazole compounds | SIGNAL PHARMACEUTICALS, LLC | 2007-03-15 | — | — | US | disclosed |
| US-20070060616-A1 | Methods for treating, preventing and managing chronic lymphocytic leukemia with indazole compounds | SIGNAL PHARMACEUTICALS, LLC | 2007-03-15 | — | — | US | disclosed |
| US-20050009876-A1 | Indazole compounds, compositions thereof and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC | 2005-01-13 | — | — | US | disclosed |
| US-20050009876-A1 | Indazole compounds, compositions thereof and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC | 2005-01-13 | — | — | US | disclosed |
| US-20040127536-A1 | Methods for treating an inflammatory condition or inhibiting JNK | SIGNAL PHARMACEUTICALS, LLC | 2004-07-01 | — | — | US | disclosed |
| US-20040127536-A1 | Methods for treating an inflammatory condition or inhibiting JNK | SIGNAL PHARMACEUTICALS, LLC | 2004-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127536-A1 | Methods for treating an inflammatory condition or inhibiting JNK | MAPK1, MAP3K1, MAPKAPK2 | CYP2C19 4372/4885ALDH1A1 2112/4885ALOX15B 1278/4885 |
| US-20070060616-A1 | Methods for treating, preventing and managing chronic lymphocytic leukemia with indazole compounds | BCL9, MCL1, INMT | CYP2C19 385/4885ALDH1A1 474/4885ALOX15B 291/4885 |
| US-20050009876-A1 | Indazole compounds, compositions thereof and methods of treatment therewith | GPR119, JAK3, IGF1R | CYP2C19 2029/4885ALDH1A1 1851/4885ALOX15B 853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.